Fractional Photothermolysis for Alopecia
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you do not use minoxidil/Rogaine, platelet-rich plasma (PRP), or light devices for hair regrowth during the study. You also should not have started using finasteride/Propecia or spironolactone in the 3 months before the study.
What data supports the effectiveness of the treatment Fractional Photothermolysis for Alopecia?
Research shows that fractional photothermolysis, when used with topical medications, improved hair regrowth and density in patients with male and female pattern hair loss. Additionally, this laser treatment has been effective in improving skin conditions like wrinkles and pigmentation, suggesting its potential for promoting healing and regeneration.12345
Is Fractional Photothermolysis safe for treating alopecia?
How does the treatment Fractional Photothermolysis for Alopecia differ from other treatments for hair loss?
Fractional Photothermolysis is unique because it uses a laser to create tiny injuries in the skin, which helps topical medications penetrate better and stimulate hair regrowth. This approach is different from standard treatments as it combines laser technology with topical drugs to enhance their effectiveness.12101112
What is the purpose of this trial?
This study is being done to evaluate the effects of fractional photothermolysis (known as laser resurfacing) using fractional laser for the induction of hair follicles via skin rejuvenation in subjects with scalp alopecia (specifically, alopecia on the superior forehead at the frontal hairline). Fractional photothermolysis has been shown to be effective in promoting hair growth. The investigators will study 50 subjects who will be treated 6-10 times at 2-4 week intervals. Each participant will have half of their head treated with a laser, either Fraxel DUAL 1550 or Halo by Sciton, and the other half of their head will be left untreated as a control. Half of the individuals will randomly be assigned to the group to be treated with Fraxel DUAL 1550, and the other half will be treated with Halo by Sciton. Visual observation and digital, photographic, non-invasive imaging will be used to compare the treated and untreated area to assess for differences in hair follicle stimulation rates, number and density of hairs.As noted above, the types of lasers we plan to use include the non-ablative fractional laser settings for the Fraxel DUAL 1550 and Halo by Sciton. A fractional laser is a laser that directs an intense burst of laser energy on the skin. The treatment deposits heat deep into the dermis to tighten skin and stimulate collagen remodeling. The necrotic (death of cells or tissue) injury heals rapidly and adverse effects are few. Laser resurfacing is commonly used for rejuvenation of the skin to improve quality, tone, and texture.
Eligibility Criteria
This trial is for people aged 18 to 90 with alopecia on the scalp, specifically at the frontal hairline. Participants should be in good health, have not received other hair loss treatments in the past month, and must commit to following the study protocol. Those with a healthy scalp without tumors are eligible; both scarring and non-scarring alopecia are acceptable.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive fractional photothermolysis treatment using either Fraxel DUAL 1550 or Halo by Sciton for hair follicle induction
Follow-up
Participants are monitored for safety and effectiveness after treatment, including hair regrowth impact on quality of life
Treatment Details
Interventions
- Fractional Photothermolysis
- Fraxel Dual laser
- Halo laser
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Irvine
Lead Sponsor
Beckman Laser Institute
Collaborator